SEC Form 4 · accession 0001209191-16-140473
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Jonathan D Feiber
10% Owner
MDV VII LP
10% Owner
Nancy J Schoendorf
10% Owner
MDV IX LP
10% Owner
Seventh MDV Partners, L.L.C.
10% Owner
Ninth MDV Partners, L.L.C.
10% Owner
MDV ENF VII (A), L.P.
10% Owner
MDV ENF VII (B), L.P.
10% Owner
MDV VII Leaders' Fund, L.P.
10% Owner
Period of report
Sep 2, 2016
Accepted (ET)
Sep 7, 2016 · 8:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 2, 2016 | P | 43,719 | $14.7515 | A | 3,816,405 | I | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP |
| Common StockF3,F2 | Sep 6, 2016 | P | 7,200 | $14.9972 | A | 3,823,605 | I | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP |
| Common StockF2 | holding | — | — | — | 265,150 | I | MDV VII, L.P. | |
| Common StockF2 | holding | — | — | — | 6,043 | I | MDV ENF VII (A), L.P. | |
| Common StockF2 | holding | — | — | — | 3,146 | I | MDV ENF VII (B), L.P. | |
| Common StockF2 | holding | — | — | — | 25,661 | I | MDV VII Leaders' Fund, L.P. | |
| Common StockF4 | holding | — | — | — | 287,992 | I | MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $14.54 and $15.00 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
- F3Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $14.70 and $15.23 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.